Valneva SE is a speciality vaccine company focused on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. Its portfolio includes three marketed vaccines: IXIARO, DUKORAL, and IXCHIQ. To maximize the value of selected programs, Valneva collaborates strategically with pharmaceutical partners, leveraging their clinical development and commercial infrastructure.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Valneva is focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical needs. The company undertakes R&D initiatives to develop vaccine candidates that are first-, best-, or only-in-class. The R&D efforts include advancing multiple vaccines from early research and development to approvals. The company's pipeline includes vaccines for infectious diseases such as chikungunya, Lyme disease, Shigella, and Zika. Valneva SE collaborates with partners like Pfizer for the development of the Lyme disease vaccine candidate VLA15 and LimmaTech for the Shigella vaccine candidate S4V2. The company invests significantly in R&D to support advancing programs through increasingly expensive stages of clinical development. Valneva Austria GmbH, located in Vienna, Austria, focuses on pre-clinical and clinical development activities of vaccines. The facilities accommodate departments for pre-clinical R&D, technical/clinical product development, quality and regulatory affairs, general and administrative, as well as commercial functions. Valneva Scotland Ltd., located in Livingston, Scotland, is primarily involved in the production of IXIARO and IXCHIQ and provides R&D support to the business as and when required. In FY2025, the company spent EUR81.4 million on its R&D activities, which as a percentage of revenue stood at 46.6% and grew 19.9% YoY. As of December 2025, the company had a portfolio of 495 issued patents, including 86 granted with effect in Germany, France, the UK, Spain, and Italy, 47 issued in the US, and 104 pending patent applications, including 16 pending in Europe and three pending international, or PCT, patent applications.